Roche Holding AG (RHHBY)
| Market Cap | 262.37B |
| Revenue (ttm) | 68.85B |
| Net Income (ttm) | 9.13B |
| Shares Out | n/a |
| EPS (ttm) | 11.38 |
| PE Ratio | 28.73 |
| Forward PE | n/a |
| Dividend | 0.86 (2.10%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 354,085 |
| Average Volume | 2,522,347 |
| Open | 41.00 |
| Previous Close | 40.77 |
| Day's Range | 39.33 - 41.10 |
| 52-Week Range | 29.20 - 44.31 |
| Beta | 0.22 |
| RSI | 48.64 |
| Earnings Date | Apr 25, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeuti...
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Blood-Based Biomarkers (BBB) Market Review 2023-2024 and Growth Opportunities 2025-2035 Featuring Profiles of Key Players - Roche, Sysmex Corporation, MiRXES, Minomic, Creative Diagnostics and More
Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Blood-Based Biomarker Market - A Global and Regional Analysis: Focus on Disease, Application, and Country-Level Analysis, 2025-2035" report has been add...
CHMP recommends EU label update for Roche's Phesgo to allow administration outside of clinical settings
Basel, 30 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recom...
David Roche: U.S. dollar is likely to drop another 15-20%, causing a sell-off of treasuries
David Roche of Quantum Strategy says a weaker dollar will drive 10-year yields to 5.5%, which will threaten the dollar's dominance. He says the Fed can do little to prevent this selling of treasuries.
'Roche could've earned over 100 times what it cost for rare disease drug'
Public health activists estimate Roche earned significantly more from risdiplam, a spinal muscular atrophy drug, than its development costs. Roche disputes this, citing expenses from unsuccessful proj...
Notable healthcare headlines for the week: Merck, Roche and Bausch Health in focus
Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5%. For the week, the S&P advanced +4
Zealand Pharma says obesity drug deal with Roche will help it stay independent
Danish biotech is developing petrelintide in partnership with the Swiss pharma group
Roche: Key Products Stall, Obesity Pipeline Takes Shape
Roche posted a Q1 revenue beat, with strong contributions from Phesgo, Xolair, and Polivy, despite larger products lagging. See why RHHBY stock is a buy.
New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission
Basel, 25 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the phase III CENTERSTONE trial of Xofluz...
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detail...
Roche Holding AG (RHHBY) Q1 2025 Sales/ Trading Statement Call Transcript
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
Roche beat first-quarter sales expectations Thursday, while Sanofi's sales report came in mixed. Shares were muted in premarket trades.
EU pharma majors Sanofi, Roche trade flat after reiterated guidance
Roche seeks US tariff relief in direct talks with Trump administration
Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the products it ships into the United States are offset by its exports of U.S.-made drugs...
Roche Sales Rise, Boosted By Key Drugs
Roche posted higher sales that beat analysts' expectations on higher demand for its key drugs.
Roche says Q1 sales up 7%, confirms guidance
Swiss drugmaker Roche said on Thursday its first-quarter sales rose 7% to 15.44 billion Swiss francs ($18.64 billion) and it confirmed its full-year guidance.
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)
Basel, 23 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of its innovative Chest Pain Triage algorithm as part of the navifyⓇ Algorithm Suite. This groundbreaking alg...
Roche’s $50bn US move fuels MEP doubts over EU’s grip on pharma
Amid fears of a pharmaceutical exodus, some MEPs are positioning the EU’s pharmaceutical package as the remedy.
Swiss pharma giant Roche pledges to invest €47 billion in the US
The investment plans include new R&D sites in four US states and creating more than 12,000 jobs, according to the Swiss pharmaceutical company.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2201330218-e972db4cd2d14caf814dfb482e2f39d4.jpg)
Swiss Pharma Giant Roche To Invest $50B in US Amid Tariff Threat
Swiss drugmaker Roche said it plans to invest $50 billion in the U.S., the latest in a string of large companies boosting their presence in the country since President Donald Trump came into office.
Swiss drugmaker Roche leans into Trump tariff formula with $50 billion promise to invest in U.S.
Roche promised that its investments in the U.S. means it will export more medicines than it imports in the U.S.
Swiss drugmaker Roche to invest $50bn in US manufacturing amid tariff fears
Company says it will create more than 12,000 new jobs as pharmaceutical industry braces for Trump levies The Swiss drugmaker Roche has announced it will put $50bn (£37bn) into manufacturing in the US ...
Swiss pharma giant Roche to invest $50 billion in US amid growing tariff uncertainty
Roche, a Swiss pharmaceutical giant, will invest $50 billion in the United States over the next five years, creating 12,000 jobs and expanding manufacturing, distribution, and research. This decision,...